Merck KGaA to acquire Bio-Techne for $11.3bn
Merck, the Darmstadt-based science and technology giant, has entered into a definitive agreement to acquire Minneapolis-based Bio-Techne Corporation. This all-cash transaction represents an enterprise value of approximately $11.3bn. The purchase price provides a 36% premium over Bio-Techne’s one-month volume-weighted average trading price, reflecting a substantial premium. From an operational standpoint, this acquisition accelerates Merck’s positioning in high-growth, next-generation life sciences…
Merck’s acquiring Terns Pharmaceuticals in $6.7bn transaction
Multinational pharma group Merck has reached a definitive agreement to acquire pharmaceutical research company Terns Pharmaceuticals in a transaction valued at approximately $6.7bn. This move is widely viewed as a strategic manoeuvre to bolster Merck’s oncology and haematology pipeline as the company prepares for the anticipated loss of exclusivity for its blockbuster cancer therapy, Keytruda, later this decade. The primary…
Merck acquiring Cidara Therapeutics in $9.2bn deal
American multinational pharmaceutical company Merck has signed a definitive agreement to acquire biotech group Cidara Therapeutics, valuing the deal at about $9.2 billion The deal is expected to close in 1Q 2026 once customary antitrust and tender-offer conditions are met. Both boards have approved the transaction. At the centre of the deal is CD388, Cidara’s first-in-class, long-acting antiviral engineered to…